Scenarios for the long-term efficacy of amyloid-targeting therapies in the context of the natural history of Alzheimer's disease
INTRODUCTION: Recent clinical trials of amyloid beta (Aβ)-targeting therapies in Alzheimer's disease (AD) have demonstrated a clinical benefit over 18 months, but their long-term impact on disease trajectory is not yet understood. We propose a framework for evaluating realistic long-term scenarios. METHODS: Results from recent phase 3 trials of Aβ-targeting antibodies were integrated with an estim